PYC reports Phase II success in treating degenerative blindness condition
PYC Therapeutics (ASX:PYC) has reported its investigational drug candidate, VP-001, has shown success in patients with Retinitis Pigmentosa type 11 (RP11) in Phase 1/2 clinical trials where improvements were reported by patients for up to 18 months after treatment. Listen to the HotCopper podcast...
Market Cap $85.28M
!
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
| Tag | Subject | ||||||
|---|---|---|---|---|---|---|---|
| NMR | Ann: NMR Receives $3M Cash from Gold Sales in September | 14/11/25 | 75 | 17K | |||
|
|||||||
| NMR | Ann: GDM:GDM to Joint Venture withNMR to Process Yellow Jack Gold | 01/11/25 | 62 | 13K | |||
|
|||||||
| NMR | Ann: Drilling confirms shallow, high-grade gold at Blackjack | 30/10/25 | 42 | 12K | |||
|
|||||||
| NMR | Ann: Notice of Annual General Meeting/Proxy Form | 29/10/25 | 0 | 195 | |||
|
|||||||
| NMR | Ann: NMR executes Sale Agreements for Palmerville Project | 27/10/25 | 2 | 669 | |||
|
|||||||
| NMR | Ann: Proposed JV with Great Divide Mining for Yellow Jack Project | 21/10/25 | 0 | 162 | |||
|
|||||||
| NMR | Ann: Change in substantial holding | 20/10/25 | 4 | 790 | |||
|
|||||||
| NMR | Ann: Change in Director's Interest Notice - Blake Cannavo | 20/10/25 | 0 | 149 | |||
|
|||||||
See All Discussions
Timeline
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
| View More | |||||
ASX News